A phase II, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of HAE1 (PRO98498) in subjects with moderate to severe allergic asthma
Latest Information Update: 10 Nov 2021
At a glance
- Drugs PRO 98498 (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors Genentech
- 01 Jan 2008 Status changed from in progress to completed.
- 15 Jun 2007 Status changed from suspended
- 27 Apr 2007 Status changed from recruiting